Skip to content

To explore the efficacy and safety of oral atorvastatin for the treatment of plaque-type psoriasis

Gov Data_NCT00929708Efficacy of AZD3199 in Chronic Obstructive Pulmonary Disease (COPD) PatientsClinicalThe purpose of this study is to investigate the efficacy, safety and tolerability of 4 weeks treatment with AZD3199 in moderate to severe COPD. The most common type is called plaque psoriasis, also known as psoriasis vulgaris. Combinations of oral treatments are particularly useful, because the doses of each drug can be reduced. Combining topical steroids with other topical drugs (see below) is often needed. Using the drug in combination with other topical and body-wide treatments may improve its effectiveness. Oral systemic medications, UV therapy, and UV therapy combined with acitretin appear to be the most cost-effective therapies for moderate to severe psoriasis. Psoriasis is a skin disorder that is characterized by scaly plaques, itching, and redness. Acitretin, Hyperlipidemia: 8.25 of patients will require lipid-lowering agents, 20 mg atorvastatin: 2.76/d (AWP), 83.

To explore the efficacy and safety of oral atorvastatin for the treatment of plaque-type psoriasis 2Background Fumaric acid esters (FAEs), an oral immunomodulating treatment for psoriasis and multiple sclerosis, have been anecdotally associated with proximal renal tubular dysfunction due to a drug-induced Fanconi syndrome. 7; see Tables 2 and 4). A second case of FAE-associated FS involved a 40-year-old female patient who had plaque psoriasis since the age of 8 years (patient no. Her medication use included atorvastatin 10 mg once daily, fluconazole 150 mg as needed and vitamin B12 injections. A topical formulation is also being investigated in phase II trials for the treatment of plaque psoriasis and atopic dermatitis. The application was filed based on the phase I pharmacokinetic studies see below. Objective To evaluate the safety and efficacy of long-term treatment of psoriasis with etanercept, 50 mg twice weekly. A total of 618 adult patients with moderate to severe plaque psoriasis were studied at 39 medical centers in the United States and Canada from

It was recently approved by the FDA in 2014 for the treatment of moderate to severe plaque psoriasis. Using the drug in combination with other topical and body-wide treatments may improve its effectiveness. Despite these side effects, oral retinoids remain among the safest whole-body therapies for psoriasis. People may see an improvement in about 4 months. Safety and efficacy of vitamin-based antioxidant therapy in patients with severe acute pancreatitis: a randomized controlled trial. Pharmacokinetics and tissue distribution studies of orally administered nanoparticles encapsulated ethionamide used as potential drug delivery system in management of multi-drug resistant tuberculosis. Efficacy and safety of combination Acitretin and Pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: a randomized, double-blind, placebo-controlled clinical trial. Comparison of alternate-day atorvastatin treatment to daily treatment in maintaining LDL-cholesterol targets in patients with variable coronary risk profile.

Drug-induced Fanconi Syndrome Associated With Fumaric Acid Esters Treatment For Psoriasis: A Case Series

Psoriasis